摘要 |
In some aspects, the invention teaches pharmaceutical compositions that include a TGF-beta ligand trap, and methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-beta ligand trap to reduce right ventricular systolic pressure in a subject. |
申请人 |
THE BRIGHAM AND WOMEN'S HOSPITAL, INC.;ACCELERON PHARMA INC. |
发明人 |
YU, PAUL;GRINBERG, ASYA;SAKO, DIANNE S.;CASTONGUAY, ROSELYNE;STEEVES, RITA;KUMAR, RAVINDRA |